The contribution of airway and lung tissue ischemia to primary graft dysfunction

Current Opinion in Organ Transplantation

Volumn 15, Issue 5, 2010, Pages 552-557

  Diamond, Joshua M ^a   Christie, Jason D ^a,b  

^a Department of Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

biomarker; ischemia reperfusion injury; lung transplantation; primary graft dysfunction

Indexed keywords

GAMMA INTERFERON; HUMAN MONOCLONAL ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN C; RECOMBINANT TISSUE FACTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AIRWAY; BLOOD CLOTTING DISORDER; BRONCHIOLITIS OBLITERANS; CELL ADHESION; CHEMOTAXIS; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LUNG ENDOTHELIUM; LUNG INJURY; LUNG LAVAGE; LUNG PARENCHYMA; LUNG PERFUSION; LUNG TISSUE ISCHEMIA; LUNG TRANSPLANTATION; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIMARY GRAFT DYSFUNCTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD COAGULATION; CHEMOTAXIS; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; LUNG; LUNG TRANSPLANTATION; PRIMARY GRAFT DYSFUNCTION; REPERFUSION INJURY; RESPIRATORY MUCOSA; RESPIRATORY TRACT DISEASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77957558294     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833e1415     Document Type: Review

References (58)

1. Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-Sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009; 28: 1031-1049.
2. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009; 28: 1007-1022.
3. Mailey B, Buchberg B, Prendergast C., et al. A disease-based comparison of liver transplantation outcomes. Am Surg 2009; 75: 901-908.
4. Bharat A, Kuo E, Steward N., et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008; 86: 189-195; discussion 196-187.
5. Bharat A, Narayanan K, Street T., et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83: 150-158.
6. Christie JD, Bavaria JE, Palevsky H.I., et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51-60.
7. Christie JD, Kotloff RM, Ahya V.N., et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171: 1312-1316.
8. Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 1232-1241.
9. Christie JD, Sager JS, Kimmel S.E., et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127: 161-165.
10. Christie JD, Van Raemdonck D, de Perrot M, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: introduction and methods. J Heart Lung Transplant 2005; 24: 1451-1453.
11. Daud SA, Yusen RD, Meyers B.F., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175: 507-513.
12. King RC, Binns OA, Rodriguez F, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69: 1681-1685.
13. Christie JD, Carby M, Bag R., et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24: 1454-1459.
14. de Perrot M., Liu M, Waddell T.K., Keshavjee S. Ischemia-reperfusion- induced lung injury. Am J Respir Crit Care Med 2003; 167: 490-511.
15. Bobadilla JL, Love RB, Jankowska-Gan E, et al. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008; 177: 660-668.
16. Pelaez A, Force SD, Gal A.A., et al. Receptor for advanced glycation end products in donor lungs is associated with primary graft dysfunction after lung transplantation. Am J Transplant 2010; 10: 900-907.
17. Christie JD, Shah CV, Kawut S.M., et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180: 1010-1015.
18. Iwata T, Philipovskiy A, Fisher AJ, et al. Antitype V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181: 5738-5747.
19. Fischer S, Cassivi SD, Xavier A.M., et al. Cell death in human lung transplantation: apoptosis induction in human lungs during ischemia and after transplantation. Ann Surg 2000; 231: 424-431.
20. Christie JD, Robinson N, Ware L.B., et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007; 175: 69-74.
21. Covarrubias M, Ware LB, Kawut S.M., et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7: 2573-2578.
22. Krenn K, Klepetko W, Taghavi S., et al. Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. Am J Transplant 2007; 7: 700-706.
23. Salama M, Andrukhova O, Hoda M.A., et al. Concomitant endothelin-1 over- expression in lung transplant donors and recipients predicts primary graft dysfunction. Am J Transplant 2010; 10: 628-636.
24. Abraham D, Taghavi S, Riml P., et al. VEGF-A and -C but not -B mediate increased vascular permeability in preserved lung grafts. Transplantation 2002; 73: 1703-1706.
25. Moreno I, Vicente R, Ramos F., et al. Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc 2007; 39: 2425-2426.
26. Ng CS, Wan S, Yim AP Pulmonary ischaemia-reperfusion injury: role of apoptosis. Eur Respir J 2005; 25: 356-363.
27. Fischer S, Maclean AA, Liu M, et al. Dynamic changes in apoptotic and necrotic cell death correlate with severity of ischemia-reperfusion injury in lung transplantation. Am J Respir Crit Care Med 2000; 162: 1932-1939.
28. Uchida T, Shirasawa M, Ware L.B., et al. Receptor for advanced glycation endproducts is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173: 1008-1015.
29. Su X, Looney MR, Gupta N, Matthay MA Receptor for advanced glycation end-products RAGE; is an indicator of direct lung injury in models of experimental lung injury. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1-5.
30. Calfee CS, Ware LB, Eisner M.D., et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63: 1083-1089.
31. Briot R, Frank JA, Uchida T, et al. Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type I cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs. Chest 2009; 135: 269-275.
32. Yoshida S, Haque A, Mizobuchi T., et al. Antitype V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well healed lung transplants. Am J Transplant 2006; 6: 724-735.
33. Haque MA, Mizobuchi T, Yasufuku K., et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169: 1542-1549.
34. Kawut SM, Okun J, Shimbo D., et al. Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 2009; 136: 237-244.
35. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-1 7-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 3498-3506.
36. Compeau CG, Ma J, DeCampos K.N., et al. In situ ischemia and hypoxia enhance alveolar macrophage tissue factor expression. Am J Respir Cell Mol Biol 1994; 11: 446-455.
37. Pinsky DJ, Liao H, Lawson C.A., et al. Coordinated induction of plasminogen activator inhibitor-1 PAI-1; and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998; 102: 919-928.
38. Ware LB, Fang X, Matthay MA Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285: L514-L521.
39. He X, Han B, Bai X., et al. PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med 2010; 36: 356-364.
40. Taghavi S, Abraham D, Riml P., et al. Co-expression of endothelin-1 and vascular endothelial growth factor mediates increased vascular permeability in lung grafts before reperfusion. J Heart Lung Transplant 2002; 21: 600-603.
41. Ware LB, Eisner MD, Thompson B.T., et al. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004; 170: 766-772.
42. Ware LB, Conner ER, Matthay MA von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001; 29: 2325-2331.
43. Rubin DB, Wiener-Kronish JP, Murray J.F., et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86: 474-480.
44. Serrick C, Adoumie R, Giaid A., Shennib H. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994; 58: 1158-1162.
45. Oz MC, Liao H, Naka Y., et al. Ischemia-induced interleukin-8 release after human heart transplantation. A potential role for endothelial cells. Circulation 1995; 92 (9 SUPPL.): II428-432.
46. Lemay S, Rabb H, Postler G., Singh AK Prominent and sustained up-regulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation 2000; 69: 959-963.
47. Gerlach J, Jorres A, Nohr R., et al. Local liberation of cytokines during liver preservation. Transpl Int 1999; 12: 261-265.
48. Matilla JM, Garcia Yuste M, Sanchez Crespo M, et al. Interleukin-8 expression in lung tissue during ischemia-reperfusion. Arch Bronconeumol 2007; 43: 542-548.
49. De Perrot M., Sekine Y, Fischer S., et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002; 165: 211-215.
50. Hoffman SA, Wang L, Shah C.V., et al. Plasma cytokines and chemokines in primary graft dysfunction postlung transplantation. Am J Transplant 2009; 9: 389-396.
51. Ingemansson R, Eyjolfsson A, Mared L., et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87: 255-260.
52. Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27: 1319-1325.
53. Cypel M, Rubacha M, Yeung J., et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9: 2262-2269.
54. Cypel M, Liu M, Rubacha M., et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1: 4ra9.
55. Yeung JC, Cypel M, Waddell T.K., et al. Update on donor assessment, resuscitation, and acceptance criteria, including novel techniques: non-heart-beating donor lung retrieval and ex vivo donor lung perfusion. Thorac Surg Clin 2009; 19: 261-274.
56. de Antonio D.G., de AV Ugarte: present state of nonheart-beating lung donation. Curr Opin Organ Transplant 2008; 13: 659-663.
57. Hicks M, Hing A, Gao L., et al. Organ preservation. Methods Molec Biol 2006; 333: 331-374.
58. Egan TM. Nonheart-beating donors in thoracic transplantation. J Heart Lung Transplant 2004; 23: 3-10.